Skip to main content
Top
Published in: Modern Rheumatology 4/2009

01-08-2009 | Original Article

Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience

Authors: Kimimasa Nakabayashi, Yoshihiro Arimura, Ken Yoshihara, Toshihiro Fukuoka, Miho Karube, Tunee Yamato, Hitoshi Koji, Noriko Ikegaya, Takako Ohtuka, Sohko Kawashima, Miyako Sudo, Akira Yamada

Published in: Modern Rheumatology | Issue 4/2009

Login to get access

Abstract

Myeloperoxidase-type antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis may manifest various organ symptoms. Treatment allows recovery from early, but severe, organ involvement. However, the relationship between the initial organ involvement and the eventual clinical course has not been studied in this disease. Therefore, the current study evaluated 30 patients who were hospitalized and then categorized into ten clinical subtypes based on organ involvement. The relationship of these subtypes to development of clinical features, patient survival, kidney prognosis, and relapse were evaluated over an average observation period of 4.3 years. During this study, the most common clinical features were lung and kidney involvement. Twenty-one patients already manifested clinical features around the time of admission and did not commonly present new symptoms as long as they were receiving the treatment for vasculitis. In contrast, as far as pulmonary involvement type at the initial time was concerned and in those not being treated for vasculitis, 7 of the 12 patients progressed to pulmo-renal involvement and 5 of them went onto renal failure. Progression to renal failure also occurred frequently in patients with pulmo-renal type manifesting at the initial time. Thirteen patients died, including three patients due to vasculitis of systemic type, seven due to infections, and three due to malignancy. Death due to vasculitis occurred in the early phase of treatment and was associated with either pulmonary hemorrhage or gastrointestinal bleeding. Infectious death occurred throughout the entire course of treatment, mostly in patients with pulmo-renal or pulmonary type, and tended to be associated with opportunistic organisms. Death with malignancy was observed after several years of treatment. Regarding renal prognosis, ten patients underwent hemodialysis. At initiation of hemodialysis, nine patients had pulmo-renal type and only one had renal type. A relapse was observed in ten patients, mainly in patients with pulmo-renal or pulmonary type, and it occurred after about 2.7 years, even with treatment. Such relapses manifested in a similar manner to their initial clinical subtypes. These results suggest that pulmo-renal type as well as pulmonary type have a high chance to progress to renal failure or systemic type, and they were fairly commonly associated with vasculitic or infectious death. Therefore, classification of clinical subtypes at the initial time and on admission is meaningful to some extent for predicting patient survival, kidney prognosis, and relapse, in addition to indicating the appropriate treatment regimen.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jennette JC, Falk RJ, Andrassy K, Bacon P, Churg J, Gross WL, et al. Nomenclature of systemic vasculitis. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef Jennette JC, Falk RJ, Andrassy K, Bacon P, Churg J, Gross WL, et al. Nomenclature of systemic vasculitis. Proposal of an international consensus conference. Arthritis Rheum. 1994;37:187–92.PubMedCrossRef
2.
go back to reference Falk RJ, Hogan S, Carey TS, Jennette JC, the Glomerular Disease Collaborative Network. Clinical course of antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113:656–63.PubMed Falk RJ, Hogan S, Carey TS, Jennette JC, the Glomerular Disease Collaborative Network. Clinical course of antineutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. Ann Intern Med. 1990;113:656–63.PubMed
3.
go back to reference Geffriand-Ricouard C, Noel LH, Chauveau D, Houhou S, Grundfeld JP, Lesavre P. Clinical spectrum associated with ANCA defined antigen specificities in 98 selected patients. Clin Nephrol. 1993;39:125–36. Geffriand-Ricouard C, Noel LH, Chauveau D, Houhou S, Grundfeld JP, Lesavre P. Clinical spectrum associated with ANCA defined antigen specificities in 98 selected patients. Clin Nephrol. 1993;39:125–36.
4.
go back to reference Hogan S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ, the Glomerular Disease Collaborative Network. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.PubMed Hogan S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ, the Glomerular Disease Collaborative Network. Prognostic markers in patients with antineutrophil cytoplasmic autoantibody-associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:23–32.PubMed
5.
go back to reference Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842–52.PubMed Westman KWA, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener’s granulomatosis or microscopic polyangiitis with renal involvement. J Am Soc Nephrol. 1998;9:842–52.PubMed
6.
go back to reference Bajema IM, Hogan EC, Hermans J, Noёl LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751–8.PubMedCrossRef Bajema IM, Hogan EC, Hermans J, Noёl LH, Waldherr R, Ferrario F, et al. Kidney biopsy as a predictor for renal outcome in ANCA-associated necrotizing glomerulonephritis. Kidney Int. 1999;56:1751–8.PubMedCrossRef
7.
go back to reference Kawamoto S, Kawamura T, Utsunomiya Y, Kawaguchi Y, Hosoya T. Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glomerulonephritis (in Japanese, abstract in English). Jpn J Nephrol. 1999;41:719–25. Kawamoto S, Kawamura T, Utsunomiya Y, Kawaguchi Y, Hosoya T. Analysis of risk factor for patients and renal survival in anti-myeloperoxidase antibody (MPO-ANCA) associated glomerulonephritis (in Japanese, abstract in English). Jpn J Nephrol. 1999;41:719–25.
8.
go back to reference Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noёl LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732–42.PubMedCrossRef Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noёl LH, Waldherr R, et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002;62:1732–42.PubMedCrossRef
9.
go back to reference Japanese Study Group for MPO-ANCA-Associated Vasculitis (JMAAV). The prospective cohort study for MPO-ANCA associated vasculitis treated according to the standard protocol regimen (directed by Prof S.Ozaki, in Japanese). 2006 Annual Report on Intractable Vasculitis Syndrome supported by the Ministry of Health, Welfare, and Labour of Japan; 2006. pp. 199–273. Japanese Study Group for MPO-ANCA-Associated Vasculitis (JMAAV). The prospective cohort study for MPO-ANCA associated vasculitis treated according to the standard protocol regimen (directed by Prof S.Ozaki, in Japanese). 2006 Annual Report on Intractable Vasculitis Syndrome supported by the Ministry of Health, Welfare, and Labour of Japan; 2006. pp. 199–273.
10.
go back to reference Nagakawa T, Arimura Y, Yoshida M, Hiromura N, Naruse T, Nishiki N, et al. Fundamental and clinical evaluation of MPO ELISA kit (NISSHO) (in Japanese). Lab Mach Reag. 1995;18:127–35. Nagakawa T, Arimura Y, Yoshida M, Hiromura N, Naruse T, Nishiki N, et al. Fundamental and clinical evaluation of MPO ELISA kit (NISSHO) (in Japanese). Lab Mach Reag. 1995;18:127–35.
11.
go back to reference Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993;86:779–89.PubMed Gordon M, Luqmani RA, Adu D, Greaves I, Richards N, Michael J, et al. Relapses in patients with a systemic vasculitis. Q J Med. 1993;86:779–89.PubMed
12.
go back to reference Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic auto-antibody associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33–4.PubMed Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response and relapse in antineutrophil cytoplasmic auto-antibody associated microscopic polyangiitis and glomerulonephritis. J Am Soc Nephrol. 1996;7:33–4.PubMed
13.
go back to reference Nakabayashi K, Kobayashi S, Matsuoka Y, Yoshida T, Yoshida M, Ozaki S, et al. Statistical analysis of infectious death in patients receiving immunosuppressive drugs with medium-and small-vessel vasculitides (in Japanese, abstract in English). 2000 Annual Report for the Refractory Vasculitis Syndrome (Chief: prof H. Hashimoto) supported by Ministry of Health, Welfare, and Labour of Japan; 2001. pp. 58–68. Nakabayashi K, Kobayashi S, Matsuoka Y, Yoshida T, Yoshida M, Ozaki S, et al. Statistical analysis of infectious death in patients receiving immunosuppressive drugs with medium-and small-vessel vasculitides (in Japanese, abstract in English). 2000 Annual Report for the Refractory Vasculitis Syndrome (Chief: prof H. Hashimoto) supported by Ministry of Health, Welfare, and Labour of Japan; 2001. pp. 58–68.
14.
go back to reference Sakai H, Kurokawa K, Koyama T, Arimura Y, Kida H, Shigematsu S, et al. The treatment guideline for rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol. 2002;44:55–82. Sakai H, Kurokawa K, Koyama T, Arimura Y, Kida H, Shigematsu S, et al. The treatment guideline for rapidly progressive glomerulonephritis (in Japanese). Jpn J Nephrol. 2002;44:55–82.
15.
go back to reference Fujii A, Tomizawa K, Arimura Y, Nagasawa T, Uhashi YY, Hiyama S, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2000;53:242–52.PubMed Fujii A, Tomizawa K, Arimura Y, Nagasawa T, Uhashi YY, Hiyama S, et al. Epitope analysis of myeloperoxidase (MPO) specific anti-neutrophil cytoplasmic autoantibodies (ANCA) in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2000;53:242–52.PubMed
Metadata
Title
Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCA-associated vasculitis: a single-center experience
Authors
Kimimasa Nakabayashi
Yoshihiro Arimura
Ken Yoshihara
Toshihiro Fukuoka
Miho Karube
Tunee Yamato
Hitoshi Koji
Noriko Ikegaya
Takako Ohtuka
Sohko Kawashima
Miyako Sudo
Akira Yamada
Publication date
01-08-2009
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 4/2009
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-009-0182-0

Other articles of this Issue 4/2009

Modern Rheumatology 4/2009 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.